- US-listed companies
- Guardant Health, Inc.
- Income statement
Guardant Health, Inc. (GH) Income statement
Market cap
$10.9B
P/E ratio
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 91 | 214 | 287 | 374 | 450 | 564 | 739 | 982 |
| Revenue growth (%) | - | |||||||
| Cost of revenue | - | - | - | - | - | - | - | 349 |
| Research & development | 51 | 86 | 150 | 263 | 374 | 367 | 348 | 364 |
| Operating margin (%) | ||||||||
| Operating expenses | 184 | 297 | 542 | 785 | 994 | 1,129 | 1,183 | 1,419 |
| Operating income | -93 | -82 | -255 | -411 | -544 | -565 | -444 | -437 |
| Income before tax | -84 | -70 | -246 | -384 | -653 | -479 | -435 | -418 |
| Pretax margin (%) | -92.9 | -32.5 | -85.8 | -102.9 | -145.4 | -84.9 | -58.9 | -42.5 |
| Provision for income taxes | 0 | -2 | 0 | 0 | 1 | 1 | 1 | -1 |
| Effective tax rate (%) | ||||||||
| Net income | -84 | -68 | -246 | -385 | -655 | -479 | -436 | -416 |
| Net income margin (%) | ||||||||
| Earnings per share | - | - | - | -4 | -6.41 | -4.28 | -3.56 | -3.32 |
| Diluted EPS | - | - | - | -4 | -6.41 | -4.28 | -3.56 | -3.32 |
| EBITDA | ||||||||
| EBITDA margin (%) |